- Reaction score
- 292
Just read this on Follicle thought, sounds pretty promising?
--------------------------
Back in August 2017, UCLA researchers made headlines by discovering a new way to activate hair follicle stem cells. This was done through a metabolite called lactate.
William Lowry and Heather Christofk of UCLA’s Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research were responsible for the lactate discovery. Lowry and Christofk found that hair follicle stem cells produce a metabolite called pyruvate. After production, the stem cells either send pyruvate into their mitochrondria or convert pyruvate into a different metabolite called lactate which activates the stem cells to produce more hair growth. The team then looked for ways to 1) diminish the entry of pyruvate into the mitochrondria and 2) increase production of lactate via the JAK-Stat pathway.
Two drugs that already existed were found to accomplish the two tasks mentioned above. A drug called RCDG423 was found to increase lactate production and another drug called UK5099 was found to block pyruvate from entering the mitochondria in hair follicle stem cells. This story caused quite a stir, but shortly thereafter the discussion on lactate for hair growth would go silent…..until now.
Enter Pelage Pharmaceuticals
On May 28th 2019 it has been announced by UCLA that Lowry, Christofk, and Michael Jung have formed a company named Pelage Pharmaceuticals to develop said compounds for human hair growth. The company is still in preclinical trials. It’s also been announced that Pelage Pharmaceuticals has entered into an agreement with Allergan (major aesthetic pharma company) to sell their entire company to Allergan if the hair growth compounds perform well in the first clinical trials. The Pelage website mentions one advantage of their technology is:
“Significantly greater efficacy than current therapies (minoxidil and finasteride)”
University research that turns into an actual company is typically few and far between. I always had a feeling that this UCLA research was going to turn into something substantial for human use. Now, here we are. Just as always, it’s going to be a number of years for this technology to go through the clinical trial process, but having a new player in the game is a valued asset for everyone. No one knows which drug in development is actually going to be the one to create a big change for those of us dealing with hair loss. I hope to be updating about a clinical trial for Pelage Pharmaceuticals as soon as possible.
Thank you for citing Follicle Thought as your source for this news.
--------------------------
Back in August 2017, UCLA researchers made headlines by discovering a new way to activate hair follicle stem cells. This was done through a metabolite called lactate.
William Lowry and Heather Christofk of UCLA’s Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research were responsible for the lactate discovery. Lowry and Christofk found that hair follicle stem cells produce a metabolite called pyruvate. After production, the stem cells either send pyruvate into their mitochrondria or convert pyruvate into a different metabolite called lactate which activates the stem cells to produce more hair growth. The team then looked for ways to 1) diminish the entry of pyruvate into the mitochrondria and 2) increase production of lactate via the JAK-Stat pathway.
Two drugs that already existed were found to accomplish the two tasks mentioned above. A drug called RCDG423 was found to increase lactate production and another drug called UK5099 was found to block pyruvate from entering the mitochondria in hair follicle stem cells. This story caused quite a stir, but shortly thereafter the discussion on lactate for hair growth would go silent…..until now.
Enter Pelage Pharmaceuticals
On May 28th 2019 it has been announced by UCLA that Lowry, Christofk, and Michael Jung have formed a company named Pelage Pharmaceuticals to develop said compounds for human hair growth. The company is still in preclinical trials. It’s also been announced that Pelage Pharmaceuticals has entered into an agreement with Allergan (major aesthetic pharma company) to sell their entire company to Allergan if the hair growth compounds perform well in the first clinical trials. The Pelage website mentions one advantage of their technology is:
“Significantly greater efficacy than current therapies (minoxidil and finasteride)”
University research that turns into an actual company is typically few and far between. I always had a feeling that this UCLA research was going to turn into something substantial for human use. Now, here we are. Just as always, it’s going to be a number of years for this technology to go through the clinical trial process, but having a new player in the game is a valued asset for everyone. No one knows which drug in development is actually going to be the one to create a big change for those of us dealing with hair loss. I hope to be updating about a clinical trial for Pelage Pharmaceuticals as soon as possible.
Thank you for citing Follicle Thought as your source for this news.